Cellromax Science Co., Ltd.
KKRX:4718204,040.00
KRW
+10.00
(+0.25%)
ISIN
KR7471820001
Return %
Stock
S&P 500
1Y
-23.34
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chang-Woo Ryu
- Full Time Employees
- 52
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Yongin-si South Korea
- IPO Date
- Dec 13, 2024
- Website
- cellromax.kr
- Similar Companies
- Business
- Cellromax Science Co., Ltd. is a South Korea-based healthcare and biotechnology company primarily engaged in the research, development, manufacturing, and distribution of health functional foods, dietary supplements, and cosmeceutical products. Founded in 2014 and headquartered in Seoul, South Korea, the company operates across the nutraceutical and pharmacy-exclusive wellness sectors, serving domestic consumers and healthcare professionals. Cellromax Science organizes its operations into dietary supplements, functional cosmetics, and pharmacy consulting solutions. The company's core product portfolio includes antioxidant formulations containing standardized anthocyanin complexes; gut microbiome and digestive health products, such as multi-strain probiotics and prebiotics; cardiovascular and metabolic wellness supplements, including purified omega-3 fatty acids; musculoskeletal support products formulated with MSM, botanical extracts, and bioactive peptides; immune-enhancing formulas; and comprehensive vitamin and mineral complexes. Under its cosmeceutical business, the company provides derma-skincare products, skin barrier repair creams, and specialized topical solutions enriched with natural plant extracts. In addition, Cellromax Science delivers specialized digital ordering services, nutritional consultation frameworks, and educational resources tailored for community pharmacies. In recent developments, the company listed its shares on the Korea Exchange (KRX: 471820) on the KONEX market to accelerate research capabilities and expand commercial operations. Cellromax Science has recently broadened its product pipeline with customized functional formulations, established strategic research collaborations with bio-ingredient developers to standardize proprietary raw materials, and initiated market expansion strategies to diversify its distribution channels beyond traditional pharmacy networks into broader healthcare markets.